Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know

Core Viewpoint - Trevi Therapeutics, Inc. (TRVI) shows significant upside potential with a mean price target of $21.22, indicating a 231.1% increase from the current price of $6.41 [1] Price Targets and Analyst Consensus - The average price target consists of nine estimates ranging from a low of $13.00 to a high of $29.00, with a standard deviation of $4.92, suggesting a variability in analyst predictions [2] - The lowest estimate indicates a potential increase of 102.8%, while the highest suggests a 352.4% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts exhibit strong agreement in revising TRVI's earnings estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 3.2%, with one estimate increasing and no negative revisions [12] - TRVI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on price targets for investment decisions may not be prudent, as analysts' price targets can often be overly optimistic due to business incentives [3][8] - While price targets should not be ignored, they should be approached with skepticism, as they may not accurately predict stock price movements [10]